Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration

Tseng, Yolanda D.; Hoppe, B.S.; Dědečková, K.; Patel, Chirayu G.; Hill‐Kayser, Christine; Miller, David; Maity, Amit; Mendenhall, Nancy P.; Vega, R. Mailhot; Yock, Torunn I.; Baliga, Sujith; Hess, Clayton B.; Winkfield, Karen M.; Mohindra, Pranshu; Rosen, L; Tsai, Henry; Chang, John; Hartsell, William F.; Plastaras, John P.

doi:10.1016/j.ijrobp.2020.08.055

Cited by 10 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanda et al [37] described an MLD of 7.2 Gy. Tseng et al [39] reported an MHD of 7.7 Gy and an MLD of 7.3 Gy. Bates et al [41] reported highly variable dosimetric values, ranging between 2.1 Gy and 19.7 Gy for MHD, between 2.9 Gy and 33.4 Gy for the left anterior descending coronary artery (LADCA), and between 0.5 Gy and 27.9 Gy for the LV.…”

Section: Radiation Exposure To Organs-at-riskmentioning

confidence: 99%

“…Ntentas et al [38] did not observe any grade 3-4 toxicity on a cohort of 21 patients treated with involved site proton therapy, with a median follow-up of 24 months. Finally, the tolerance profile of proton therapy in the case of relapse/refractory (r/r) HL has also been evaluated by Tseng et al [39] on a cohort of 85 r/r lymphoma patients (including 56 HL patients) treated to a median dose of 36 Gy. With a median follow-up of 26.3 months, no grade 3-4 pulmonary toxicity was observed; grade 2 pneumonitis (12.8% of the patients) could be predicted based on mean lung dose (MLD), lung V5Gy and V20Gy.…”

Section: Clinical Tolerance and Efficacy Datamentioning

confidence: 99%

“…Yet, the development of NTCP models need long-term follow-up and robust dosimetric data. While acute pneumonitis risk for HL proton therapy might be extrapolated from r/r HL proton therapy study by Tseng et al [39], prediction of late toxicity risk could currently solely rely on photon NTCP models, which completely disregards specific radiobiological effect of proton beams [46] and relative biological effectiveness (RBE) variation issues [47,48]. There is consequently a need for larger population HL proton therapy studies to evaluate long-term adverse events and propose toxicity prediction models.…”

Section: The Need For a Longer Follow-upmentioning

confidence: 99%

“…Published clinical data (2014-2021) on radiation exposure to organs-at-risk for Hodgkin lymphoma (HL) patients treated with proton therapy. Nanda et al[37] and Tseng et al[39] included non-Hodgkin lymphoma (NHL) patients in their studies. Pts.…”

mentioning

confidence: 99%

“…RV: right ventricle. Nanda et al[37] and Tseng et al[39] included non-Hodgkin lymphoma (NHL) patients in their studies. Grey areas: dosimetric data not available.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence

Loap

Mirandola

Marzi

et al. 2021

Cancers

View full text Add to dashboard Cite

Consolidative radiation therapy (RT) is of prime importance for early-stage Hodgkin lymphoma (HL) management since it significantly increases progression-free survival (PFS). Nevertheless, first-generation techniques, relying on large irradiation fields, delivered significant radiation doses to critical organs-at-risk (OARs, such as the heart, to the lung or the breasts) when treating mediastinal HL; consequently, secondary cancers, and cardiac and lung toxicity were substantially increased. Fortunately, HL RT has drastically evolved and, nowadays, state-of-the-art RT techniques efficiently spare critical organs-at-risks without altering local control or overall survival. Recently, proton therapy has been evaluated for mediastinal HL treatment, due to its possibility to significantly reduce integral dose to OARs, which is expected to limit second neoplasm risk and reduce late toxicity. Nevertheless, clinical experience for this recent technique is still limited worldwide. Based on current literature, this critical review aims to examine the current practice of proton therapy for mediastinal HL irradiation.

show abstract

Section: Radiation Exposure To Organs-at-riskmentioning

confidence: 99%

Section: Clinical Tolerance and Efficacy Datamentioning

confidence: 99%

Section: The Need For a Longer Follow-upmentioning

confidence: 99%

mentioning

confidence: 99%

“…RV: right ventricle. Nanda et al[37] and Tseng et al[39] included non-Hodgkin lymphoma (NHL) patients in their studies. Grey areas: dosimetric data not available.…”

mentioning

confidence: 99%

See 3 more Smart Citations